License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
License And Collaboration Agreements [Line Items]
Accrued expenses and other current liabilities		$ 2,404		$ 2,404
Research and development costs		27,391	$ 26,411	79,487	$ 50,947
Harbour License Agreement [Member]
License And Collaboration Agreements [Line Items]
Upfront license fee				25,000
Harbour BioMed US Inc. [Member] | Harbour License Agreement [Member]
License And Collaboration Agreements [Line Items]
Upfront license fee				25,000
Harbour BioMed US Inc. [Member] | Maximum | Harbour License Agreement [Member] | Achievement Based [Member]
License And Collaboration Agreements [Line Items]
Aggregate amount of milestone payment				148,000
Harbour BioMed US Inc. [Member] | Maximum | Harbour License Agreement [Member] | Sales Based [Member]
License And Collaboration Agreements [Line Items]
Aggregate amount of milestone payment				415,000
Pearl - Taiho
License And Collaboration Agreements [Line Items]
Percentage of profits from potential sales	50.00%
Research and development expense related to share of costs		5,500		10,200
Accrued expenses and other current liabilities		3,400		3,400
Research and development costs		$ 2,100		3,100
Adimab
License And Collaboration Agreements [Line Items]
Research and development costs					500
MIT
License And Collaboration Agreements [Line Items]
Research and development costs			$ 200	$ 200	$ 200